Company Filing History:
Years Active: 2014-2016
Title: Ian Richard Catchpole: Innovator in Antigen Binding Constructs
Introduction
Ian Richard Catchpole is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of biotechnology, particularly in the development of antigen binding constructs. With a total of 3 patents to his name, Catchpole's work focuses on addressing critical health issues through innovative solutions.
Latest Patents
One of Catchpole's latest patents is centered around antigen binding constructs that comprise one or two epitope binding domains separated by a single chain Fc region of an antibody. These constructs are designed to bind to VEGF and are applicable in treating diseases associated with VEGF signaling, such as diabetic macular edema (DME) and wet age-related macular degeneration (Wet AMD). Another significant patent involves humanized anti-beta-amyloid antibodies, which target the beta-amyloid peptide, particularly in relation to Alzheimer's disease and other disorders characterized by elevated beta-amyloid levels.
Career Highlights
Ian Richard Catchpole is currently associated with Glaxo Group Limited, where he continues to advance his research and development efforts. His work has been instrumental in creating pharmaceutical compositions that utilize his patented technologies to combat serious health conditions.
Collaborations
Catchpole has collaborated with notable colleagues, including Jonathan Henry Ellis and Susannah Karen Ford, to further enhance the impact of his inventions in the medical field.
Conclusion
Ian Richard Catchpole's innovative contributions to biotechnology, particularly in the realm of antigen binding constructs, highlight his commitment to improving health outcomes. His patents reflect a dedication to addressing significant medical challenges through scientific advancement.